Can serum TGF-beta 1 be used to evaluate the response to antiviral therapy of haemophilic patients with HCV-related chronic hepatitis? (Q45882492)

17 December 2017

title

Can serum TGF-beta 1 be used to evaluate the response to antiviral therapy of haemophilic patients with HCV-related chronic hepatitis? (English)

1 reference

17 December 2017

0 references

G Tarantino

1

1 reference

17 December 2017

A Coppola

2

1 reference

17 December 2017

P Conca

3

1 reference

17 December 2017

E Cimino

4

1 reference

17 December 2017

G Di Minno

5

1 reference

17 December 2017

language of work or name

1 reference

1 October 2008

1 reference

17 December 2017

International Journal of Immunopathology and Pharmacology

published in

1 reference

17 December 2017

volume

21

1 reference

17 December 2017

issue

4

1 reference

17 December 2017

page(s)

1007-1012

1 reference

17 December 2017

Are chronic hepatitis C viral infections more benign in patients with hemophilia?

cites work

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Liver biopsy in Irish hepatitis C-infected patients with inherited bleeding disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Transjugular liver biopsy is a safe and effective intervention to guide management for patients with a congenital bleeding disorder infected with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Usefulness of elastometry in evaluating the extents of liver fibrosis in hemophiliacs coinfected with hepatitis C virus and human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

TGF-beta1 mRNA expression in liver biopsy specimens and TGF-beta1 serum levels in patients with chronic hepatitis C before and after antiviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Transforming growth factor beta in hepatitis C virus infection: in vivo and in vitro findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Viral factors associated with cytokine expression during HCV/HIV co-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Histological response to interferon alfa-based therapies in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Hepatitis C Virus (HCV)-Specific CD8+ Cells Produce Transforming Growth Factor That Can Suppress HCV-Specific T-Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

Parenchymal transforming growth factor beta-1: Its type II receptor and Smad signaling pathway correlate with inflammation and fibrosis in chronic liver disease of viral etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F039463200802100426

10.1177/039463200802100426

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

PubMed ID

19144287

1 reference

17 December 2017